share_log

Jefferies Downgrades TCR2 Therapeutics to Underperform, Lowers Price Target to $3

Jefferies Downgrades TCR2 Therapeutics to Underperform, Lowers Price Target to $3

杰富瑞将TCR2 Therapeutics的评级下调至表现不佳,将目标股价下调至3美元
Benzinga ·  2023/03/09 06:00

Jefferies analyst Kelly Shi downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Underperform and lowers the price target from $18 to $3.

杰富瑞分析师Kelly Shih将TCR2治疗公司(纳斯达克:TCRR)的评级从买入下调至表现不佳,并将目标价从18美元下调至3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发